Rivaroxaban
Concept
Vocabulary Service
Overview
subject area of
-
A Replacement for Warfarin Academic Article
-
A hybrid automated event adjudication system for clinical trials Academic Article
-
A logical approach to surgical thromboprophylaxis Academic Article
-
A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment Academic Article
-
A phase 2 PK/PD study of andexanet alfa for reversal of rivaroxaban and edoxaban anticoagulation in healthy volunteers Academic Article
-
A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban Academic Article
-
A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2) Academic Article
-
Accumulating data on rivaroxaban for venous thromboembolism in clinical practice Academic Article
-
Accuracy of a Rapid Diagnostic Test for the Presence of Direct Oral Factor Xa or Thrombin Inhibitors in Urine—A Multicenter Trial Academic Article
-
Acute management of bleeding in patients on novel oral anticoagulants Academic Article
-
Advances in Antithrombotic Therapy Academic Article
-
Advances in the management of venous thromboembolism. Academic Article
-
Advantages and limitations of the new anticoagulants Academic Article
-
After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding Academic Article
-
An assay to measure levels of factor Xa inhibitors in blood and plasma Academic Article
-
Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study Academic Article
-
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors Academic Article
-
Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity Academic Article
-
Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis Academic Article
-
Anti-thrombotic options for secondary prevention in patients with chronic atherosclerotic vascular disease: what does COMPASS add? Academic Article
-
Antiplatelet therapy in the management of atherothrombosis: recent clinical advances Academic Article
-
Antithrombotic Agents Academic Article
-
Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making Academic Article
-
Antithrombotic drug removal from whole blood using Haemoadsorption with a porous polymer bead sorbent Academic Article
-
Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source Academic Article
-
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Academic Article
-
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Academic Article
-
Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials Academic Article
-
Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty Academic Article
-
Assays for Measuring Rivaroxaban: Their Suitability and Limitations Academic Article
-
Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes Academic Article
-
Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials Academic Article
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation Academic Article
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism Academic Article
-
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism Academic Article
-
Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source Academic Article
-
BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study Academic Article
-
Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach Academic Article
-
Barriers and facilitators to optimal oral anticoagulant management: a scoping review Academic Article
-
Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty Academic Article
-
Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin Academic Article
-
Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness Academic Article
-
Beyond Unfractionated Heparin and Warfarin Academic Article
-
Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis Academic Article
-
Bleeding and antidotes in new oral anticoagulants Academic Article
-
Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study Academic Article
-
Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience Academic Article
-
Bleeding with direct oral anticoagulants vs warfarin: clinical experience Academic Article
-
Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design Academic Article
-
Broadening the Categories of Patients Eligible for Extended Venous Thromboembolism Treatment Academic Article
-
COMPASS for Vascular Surgeons Academic Article
-
Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease Academic Article
-
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF Academic Article
-
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source Academic Article
-
Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial Academic Article
-
Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials Academic Article
-
Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism Academic Article
-
Clinical implications of reversal agents for direct oral anticoagulants Academic Article
-
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications Academic Article
-
Coagulation assays and direct oral anticoagulant levels among patients having an elective surgery or procedure Academic Article
-
Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial Academic Article
-
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development Academic Article
-
Comparative effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists in nonvalvular atrial fibrillation: a Canadian multicentre observational cohort study Academic Article
-
Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study Academic Article
-
Comparison of Investigator-Reported vs Centrally Adjudicated Major Adverse Cardiac Events Academic Article
-
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents Academic Article
-
Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers Academic Article
-
Continued vs. interrupted direct oral anticoagulants at the time of device surgery, in patients with moderate to high risk of arterial thrombo-embolic events (BRUISE CONTROL-2) Academic Article
-
Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation Academic Article
-
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada Academic Article
-
Derivation and validation of predictors of oral anticoagulant-related adverse events in seniors transitioning from hospital to home Academic Article
-
Design of the rivaroxaban for heparin-induced thrombocytopenia study Academic Article
-
Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies Academic Article
-
Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information Academic Article
-
Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Academic Article
-
Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review Academic Article
-
Direct oral anticoagulants: evidence and unresolved issues Academic Article
-
Dual Pathway Inhibition for Vascular Protection in Patients with Atherosclerotic Disease: Rationale and Review of the Evidence Academic Article
-
Dual pathway inhibition for atherosclerotic cardiovascular disease: Recent advances. Academic Article
-
Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial Academic Article
-
Effect of extended‐duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis Academic Article
-
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Frail Patients with Venous Thromboembolism Academic Article
-
Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis Academic Article
-
Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state Academic Article
-
Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism Academic Article
-
Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism Academic Article
-
Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1 Academic Article
-
Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants Academic Article
-
Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis Academic Article
-
Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease Academic Article
-
Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: A post hoc analysis of a “CASPAR like” outcome from VOYAGER PAD Academic Article
-
Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty Academic Article
-
Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial Academic Article
-
Evolving use of new oral anticoagulants for treatment of venous thromboembolism Academic Article
-
External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry Academic Article
-
External applicability of the COMPASS trial: the Western Denmark Heart Registry Academic Article
-
Factor Xa and thrombin as targets for new oral anticoagulants Academic Article
-
Fondaparinux cross-reactivity in heparin-induced thrombocytopenia successfully treated with high-dose intravenous immunoglobulin and rivaroxaban Academic Article
-
Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial Academic Article
-
Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source Academic Article
-
Functional Abilities of an International Post-Stroke Population: Standard Assessment of Global Everyday Activities (SAGEA) Scale Academic Article
-
Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies Academic Article
-
Global Prospective Safety Analysis of Rivaroxaban Academic Article
-
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease Academic Article
-
Healthcare resource use in XALIA: A subgroup analysis of a non-interventional study of rivaroxaban versus standard anticoagulation for deep vein thrombosis Academic Article
-
Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy Academic Article
-
High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source Academic Article
-
Higher-risk APS: do we dare to DOAC? Academic Article
-
How I treat heavy menstrual bleeding associated with anticoagulants Academic Article
-
How I treat target-specific oral anticoagulant–associated bleeding Academic Article
-
How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Academic Article
-
ISTH guidelines for antithrombotic treatment in COVID‐19 Academic Article
-
Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban Academic Article
-
Impact of Prolonged Anticoagulation with Rivaroxaban on Provoked Venous Thromboembolism Recurrence: IMPROVE-VTE Academic Article
-
Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy Academic Article
-
Impact of gender: Rivaroxaban for patients with atrial fibrillation in the
XANTUS
real‐world prospective study Academic Article
-
In high-risk patients with cancer, thromboprophylaxis with rivaroxaban did not reduce VTE events at 180 days Academic Article
-
Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation Academic Article
-
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome Academic Article
-
International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants Academic Article
-
Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy Academic Article
-
Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials Academic Article
-
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants Academic Article
-
Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation Academic Article
-
Laboratory measurement of the direct oral anticoagulants Academic Article
-
Left Atrial Enlargement Could Be Detected on Extended Computed Tomography Angiography Within Initial Stroke Assessment—Reply Academic Article
-
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin Academic Article
-
Less menorrhagia for women with VTE Academic Article
-
Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials Academic Article
-
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial Academic Article
-
Low molecular weight heparin anti-Xa assays can identify patients with clinically important apixaban and rivaroxaban drug levels Academic Article
-
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials Academic Article
-
Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS Academic Article
-
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial Academic Article
-
Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial Academic Article
-
Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease Academic Article
-
Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin Academic Article
-
Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor Academic Article
-
Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy Academic Article
-
Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study Academic Article
-
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting Academic Article
-
Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source Academic Article
-
Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent Academic Article
-
Monitoring and reversal of direct oral anticoagulants Academic Article
-
Monitoring the anticoagulant effect after a massive rivaroxaban overdose Academic Article
-
Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease Academic Article
-
Mortality benefit in the COMPASS trial: is it related to superior statistical power or better efficacy and safety? Academic Article
-
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank Academic Article
-
New Anticoagulants for Atrial Fibrillation Academic Article
-
New Anticoagulants for Treatment of Venous Thromboembolism Academic Article
-
New Anticoagulants for the Prevention of Thromboembolism Academic Article
-
New Antithrombotic Drugs: Potential for Use in Oncology Academic Article
-
New oral anticoagulant agents – general features and outcomes in subsets of patients Academic Article
-
New oral anticoagulants and oculoplastic surgery Academic Article
-
New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions Academic Article
-
New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty Academic Article
-
New oral anticoagulants in elderly patients Academic Article
-
New oral anticoagulants: not quite there yet Academic Article
-
New oral anticoagulants: which one should my patient use? Academic Article
-
Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study Academic Article
-
Novel Oral Anticoagulants: A Focused Review for Stroke Physicians Academic Article
-
Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism Academic Article
-
Novel oral anticoagulants in gastroenterology practice Academic Article
-
Novel oral anticoagulants in secondary prevention of stroke Academic Article
-
Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants Academic Article
-
Oral Anticoagulant Therapy Academic Article
-
Oral Rivaroxaban for Symptomatic Venous Thromboembolism Academic Article
-
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism Academic Article
-
Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives Academic Article
-
Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease Academic Article
-
Oral factor Xa inhibitors and risk of subdural hematoma Academic Article
-
Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement Academic Article
-
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases Academic Article
-
Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study Academic Article
-
Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study Academic Article
-
Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Academic Article
-
Overview of Therapeutic Approaches for Cholesterol Lowering and Attenuation of Thrombosis for Prevention of Atherothrombosis Academic Article
-
Overview of the New Oral Anticoagulants Academic Article
-
Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease Academic Article
-
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial Academic Article
-
Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry Academic Article
-
Patients with Peripheral Artery Disease in the COMPASS Trial Academic Article
-
Pattern of Atrial Fibrillation and Cognitive Function in Young Patients With Atrial Fibrillation and Low CHADS
2
Score: Insights From the BRAIN-AF Trial Academic Article
-
Perioperative management of patients who are receiving a novel oral anticoagulant Academic Article
-
Periprocedural Management of Oral Anticoagulation Academic Article
-
Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy Academic Article
-
Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management Academic Article
-
Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery Academic Article
-
Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients Academic Article
-
Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial Academic Article
-
Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study Academic Article
-
Potential of new anticoagulants in patients with cancer Academic Article
-
Practical aspects of new oral anticoagulant use in atrial fibrillation Academic Article
-
Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk Academic Article
-
Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban Academic Article
-
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study Academic Article
-
Predictors of Bleeding in the Perioperative Anticoagulant Use for Surgery Evaluation Study Academic Article
-
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial Academic Article
-
Predictors of preprocedural direct oral anticoagulant levels in patients having an elective surgery or procedure Academic Article
-
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone Academic Article
-
Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial Academic Article
-
Procoagulants for management of bleeding with the new oral anticoagulants Academic Article
-
Prothrombin Complex Concentrate for Major Bleeding on Factor Xa Inhibitors: A Prospective Cohort Study Academic Article
-
Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD) Academic Article
-
Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery Academic Article
-
Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial Academic Article
-
Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS Academic Article
-
Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation Academic Article
-
Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism Academic Article
-
Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD Academic Article
-
Reply Academic Article
-
Reply Academic Article
-
Reply Academic Article
-
Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban Academic Article
-
Resident Physicians Choices of Anticoagulation for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation Academic Article
-
Response to the Letter by Spurling and Colleagues Academic Article
-
Reversal of Direct Oral Anticoagulants: Current Status and Future Directions Academic Article
-
Reversal of direct oral anticoagulants: a practical approach Academic Article
-
Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit) Academic Article
-
Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial Academic Article
-
Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants Academic Article
-
Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population-based cohort study Academic Article
-
Risk of recurrent venous thromboembolism according to baseline risk factor profiles Academic Article
-
Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis Academic Article
-
Rivaroxaban Compared to Placebo for the Treatment of Leg Superficial Vein Thrombosis: A Randomized Trial Academic Article
-
Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Academic Article
-
Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial Academic Article
-
Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction Academic Article
-
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease Academic Article
-
Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease Academic Article
-
Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization Academic Article
-
Rivaroxaban and Aspirin in Peripheral Vascular Disease: a Review of Implementation Strategies and Management of Common Clinical Scenarios Academic Article
-
Rivaroxaban and Dabigatran for Suppression of Mechanical Heart Valve–Induced Thrombin Generation Academic Article
-
Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization Academic Article
-
Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro Academic Article
-
Rivaroxaban and aspirin vs. aspirin alone in Asian compared with non-Asian patients with chronic coronary artery disease or peripheral arterial disease: the COMPASS trial Academic Article
-
Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography Academic Article
-
Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial Academic Article
-
Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co‐medication interactions Academic Article
-
Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial Academic Article
-
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline Academic Article
-
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source Academic Article
-
Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice Academic Article
-
Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness Academic Article
-
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer Academic Article
-
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older Academic Article
-
Rivaroxaban for prevention and treatment of venous thromboembolism Academic Article
-
Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial Academic Article
-
Rivaroxaban for the prevention and treatment of venous thromboembolism Academic Article
-
Rivaroxaban for the prevention of major adverse cardiovascular events in patients with coronary or peripheral artery disease Academic Article
-
Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty Academic Article
-
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies Academic Article
-
Rivaroxaban for treatment of HIT: A riveting first experience Academic Article
-
Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein‐Jr phase 3 dose‐exposure‐response evaluation Academic Article
-
Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia study Academic Article
-
Rivaroxaban in Orthopedic Surgery — A Change of Paradigm? Academic Article
-
Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment Academic Article
-
Rivaroxaban in Peripheral Artery Disease after Revascularization Academic Article
-
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation Academic Article
-
Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation Academic Article
-
Rivaroxaban in Stable Cardiovascular Disease Academic Article
-
Rivaroxaban in patients with symptomatic peripheral artery disease after lower extremity bypass surgery with venous and prosthetic conduits Academic Article
-
Rivaroxaban in treatment refractory heparin-induced thrombocytopenia Academic Article
-
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism Academic Article
-
Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial Academic Article
-
Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition Academic Article
-
Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers Academic Article
-
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty Academic Article
-
Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy Academic Article
-
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial Academic Article
-
Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial Academic Article
-
Rivaroxaban versus enoxaparin after total knee arthroplasty Academic Article
-
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial Academic Article
-
Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study Academic Article
-
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial Academic Article
-
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease Academic Article
-
Rivaroxaban with or without aspirin for prevention of cardiovascular disease Academic Article
-
Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
-
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial Academic Article
-
Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion Academic Article
-
Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease Academic Article
-
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study Academic Article
-
Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE) Academic Article
-
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin Academic Article
-
Selective factor Xa inhibition for thromboprophylaxis Academic Article
-
Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment Academic Article
-
Sex‐Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD Academic Article
-
Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial Academic Article
-
Stroke Outcomes in the COMPASS Trial Academic Article
-
Stroke Prevention in Atrial Fibrillation Academic Article
-
Stroke and Thromboembolism in Patients with Heart Failure and Sinus Rhythm: A Matter of Risk Stratification? Academic Article
-
Stroke prevention in atrial fibrillation: Closing the gap Academic Article
-
Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease Academic Article
-
The COMPASS Trial Academic Article
-
The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population Academic Article
-
The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation Academic Article
-
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE Academic Article
-
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V—Special Situations Academic Article
-
The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial Academic Article
-
The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale Academic Article
-
The effects of rivaroxaban on the complications of surgery after total hip or knee replacement Academic Article
-
The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study Academic Article
-
The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients Academic Article
-
The top 4 advances in antithrombotic care in the last year Academic Article
-
Thromboprophylaxis after knee arthroscopy does not decrease the risk of deep vein thrombosis: a network meta-analysis Academic Article
-
Thromboprophylaxis with Rivaroxaban in Acutely Ill Medical Patients with Renal Impairment: Insights from the MAGELLAN and MARINER Trials Academic Article
-
Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding Academic Article
-
Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies Academic Article
-
Treatment of venous thromboembolism with dabigatran Academic Article
-
Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014 Academic Article
-
Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism Academic Article
-
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study Academic Article
-
Urgent procedures or surgeries in patients receiving oral anticoagulants: a systematic literature review Academic Article
-
Utility of a Nurse-Led Pathway for Patients with Acute Venous Thromboembolism Discharged on Rivaroxaban: A Prospective Cohort Study Academic Article
-
Venous thromboembolism management: where do novel anticoagulants fit? Academic Article
-
What is the effect of rivaroxaban on routine coagulation tests? Academic Article
-
XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America Academic Article
-
XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation Academic Article
-
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation Academic Article
-
Xarelto plus Acetylsalicylic acid: Treatment patterns and Outcomes in patients with Atherosclerosis (XATOA): Rationale and design of a prospective registry study to assess rivaroxaban 2.5 mg twice daily plus aspirin for prevention of atherothrombotic events in coronary artery disease, peripheral artery disease, or both Academic Article